MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$2,630,623
Free Cash flow
-$2,596,821
Unit: Dollar
Positive Cash Flow Breakdown
    • Accrued expenses
    • Accounts payable
    • Non-cash lease expense
    • Depreciation expense
Negative Cash Flow Breakdown
    • Net loss
    • Prepaid expenses and other curre...
    • Purchase of property and equipme...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,323,384
-3,009,051
-2,511,006
-6,402,643
Stock-based compensation expense
401,417
470,997
370,166
225,202
Non-cash lease expense
56,146
55,699
18,630
-
Depreciation expense
8,313
7,203
5,852
21,206
Loss on disposal of equipment
-
-
0
-11,207
Change in fair value of warrant liability
-
-
-87
-2,071
Prepaid expenses and other current assets
109,104
39,297
-12,637
57,235
Other assets
-
-
30,941
-
Accounts payable
136,692
216,900
-442,450
236,330
Accrued expenses
291,855
-929,562
604,341
-334,585
Operating lease liability
-19,128
12,260
5,866
-
Net cash used in operating activities
-2,557,193
-3,214,851
-1,966,992
-6,302,589
Proceeds from public offering, net-May2025Public Offering
-
-
0
3,388,244
Proceeds from warrant exercise-Class HPre Funded Warrants
-
-
0
297
Proceeds from warrant exercise-Class HCommon Stock Warrants
-
-
363,000
-
Purchase of property and equipment
39,628
71,879
-
-
Proceeds from warrant exercise-Warrant Inducement
-
-
-41,166
8,760,519
Net cash used in investing activities
-39,628
-71,879
-
-
Proceeds from warrant exercise-Class HWarrants
-
-
-
363,000
Proceeds from warrant inducement exercises, net
-33,802
6,699,814
-
-
Net cash provided by financing activities
-33,802
6,699,814
-41,166
12,512,060
Net increase (decrease) in cash and cash equivalents
-2,630,623
3,413,084
-2,008,158
6,209,471
Cash and cash equivalents at beginning of period
14,113,415
10,700,331
12,708,489
6,499,018
Cash and cash equivalents at end of period
11,482,792
14,113,415
10,700,331
12,708,489
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase(decrease) in cash and cash...-$2,630,623 Stock-based compensationexpense$401,417 Accrued expenses$291,855 Accounts payable$136,692 Non-cash lease expense$56,146 Depreciation expense$8,313 Net cash used inoperating activities-$2,557,193 Net cash used ininvesting activities-$39,628 Net cash provided byfinancing activities-$33,802 Canceled cashflow$894,423 Net loss-$3,323,384 Purchase of property andequipment$39,628 Proceeds from warrantinducement exercises, net-$33,802 Prepaid expenses andother current assets$109,104 Operating lease liability-$19,128

REVELATION BIOSCIENCES, INC. (REVB)

REVELATION BIOSCIENCES, INC. (REVB)